Skip to main content

Table 3 Comparison of cardiovascular risk factors at baseline—all randomized patients (ITT population)

From: Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

Variable

All comparators

(N = 2125)

n (%)

All dulaglutide

(N = 3885)

n (%)

Total

(N = 6010)

n (%)

p valuea

Prior MI

51 (2.4)

132 (3.4)

183 (3.0)

0.049

History of unstable angina

34 (1.6)

55 (1.4)

89 (1.5)

0.632

Prior coronary revascularization

65 (3.1)

115 (3.0)

180 (3.0)

0.738

History of stroke or TIA

35 (1.7)

63 (1.6)

98 (1.6)

0.979

History of heart failure

12 (0.6)

16 (0.4)

28 (0.5)

0.284

History of (documented) coronary artery disease

86 (4.1)

189 (4.9)

275 (4.6)

0.163

Has hypertension

1357 (63.9)

2451 (63.1)

3808 (63.4)

0.504

Has hyperlipidemiab

1176 (55.3)

2116 (54.5)

3292 (54.8)

0.296

History of carotid revascularizationc

4 (0.2)

8 (0.2)

12 (0.2)

0.863

History of lower extremity arterial revascularizationc

7 (0.5)

8 (0.3)

15 (0.3)

0.380

History of peripheral vascular diseasec

30 (1.4)

57 (1.5)

87 (1.5)

0.962

History of atrial fibrillationc

30 (1.4)

38 (1.0)

68 (1.1)

0.173

Current smoker

335 (15.9)

551 (14.3)

886 (14.8)

0.101

Current smoker with hypertension and hyperlipidemia

138 (6.5)

217 (5.6)

355 (5.9)

0.161

Kidney function group by eGFR

–

–

–

0.899

 <30 mL/min/1.73 m2

1 (0.1)

2 (0.1)

3 (0.1)

 

 30 ≤ eGFR < 60 mL/min/1.73 m2

126 (5.9)

228 (5.9)

354 (5.9)

 

 ≥60 mL/min/1.73 m2

1998 (94.0)

3654 (94.1)

5652 (94.1)

 

Albuminuria group by urine ACRd

–

–

–

0.433

 <30 mg/g

1566 (76.8)

2811 (77.1)

4377 (77.0)

 

 30 ≤ Urine ACR ≤ 300 mg/g

395 (19.4)

713 (19.6)

1108 (19.5)

 

 >300 mg/g

79 (3.9)

121 (3.3)

200 (3.5)

 
  1. eGFR estimated glomerular filtration rate, HDL high density lipoprotein, LDL low density lipoprotein, MI myocardial infarction, TIA transient ischemic attack, urine ACR urinary albumin/creatinine ratio
  2. aTreatments were compared by Cochran–Mantel–Haenszel test. Strata = studies
  3. bHaving hyperlipidemia or taking lipid lowering drugs at baseline or having LDL-C ≥160 mg/dL or HDL-C <40 mg/dL or triglycerides ≥200 mg/dL. Missing value was set to category ‘No’
  4. cCV risk factors were either collected directly or were identified by searching historical events and pre-existing events at baseline with relevant preferred terms. Missing value is set to category ‘No’. History of lower extremity arterial revascularization was not collected, could not be defined, and is missing for the dose titration study, the monotherapy study, and AWARD-5 study
  5. dUrine ACR was not collected in the dose titration study
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840